BioNano Genomics, Inc. (BNGO)

Market Cap	620.57M
Revenue (ttm)	25.89M
Net Income (ttm)	-116.87M
Shares Out	289.70M
EPS (ttm)	-0.33
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,381,891
Open	2.16
Previous Close	2.09
Day's Range	1.98 - 2.17
52-Week Range	1.16 - 4.35
Beta	2.26
Analysts	Buy
Price Target	8.84 (+343.1%)
Earnings Date	Nov 3, 2022

About BNGO

Bionano Genomics, Inc. provides genome analysis software solutions. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight. The company also provides Sap...

• Industry: Life Sciences Tools & Services
• IPO Date: Aug 21, 2018
• CEO: R. Erik Holmlin
• Employees: 299
• Stock Exchange: NASDAQ
• Ticker Symbol: BNGO

Financial Performance

In 2021, BNGO's revenue was $17.98 million, an increase of 111.47% compared to the previous year's $8.50 million. Losses were -$72.44 million, 76.2% more than in 2020.

Analyst Forecast

According to 9 analysts, the average rating for BNGO stock is "Buy." The 12-month stock price forecast is 8.84, which is an increase of 343.11% from the latest price.

Price Target

$8.84

(343.11% upside)

Analyst Consensus: Buy